Mobilization of circulating endothelial progenitor cells correlates with the clinical course of hantavirus disease

Journal of Virology

Volumn 88, Issue 1, 2014, Pages 483-489

  Krautkrämer, Ellen ^a   Grouls, Stephan ^a   Hettwer, David ^a   Rafat, Neysan ^b   Tönshoff, Burkhard ^b   Zeier, Martin ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANGIOPOIETIN 2; C REACTIVE PROTEIN; CD133 ANTIGEN; CD31 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; CREATININE; LACTATE DEHYDROGENASE; STROMAL CELL DERIVED FACTOR 1ALPHA; VASCULOTROPIN;

ACUTE KIDNEY FAILURE; ADULT; AGE DISTRIBUTION; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE COURSE; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM LESION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HANTAVIRUS; HANTAVIRUS INFECTION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; STEM CELL MOBILIZATION; THROMBOCYTE COUNT; UPREGULATION; VIRUS HEMORRHAGIC FEVER;

ADULT; CASE-CONTROL STUDIES; CYTOKINES; ENDOTHELIAL CELLS; FEMALE; HANTAVIRUS INFECTIONS; HUMANS; MALE; MIDDLE AGED; STEM CELLS;

EID: 84890862250     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02063-13     Document Type: Article

References (63)

1. Baskerville A, Fisher-Hoch SP, Neild GH, Dowsett AB. 1985. Ultrastructural pathology of experimental Ebola haemorrhagic fever virus infection. J. Pathol. 147:199-209. http://dx.doi.org/10.1002/path.1711470308.
2. Jessie K, Fong MY, Devi S, Lam SK, Wong KT. 2004. Localization of dengue virus in naturally infected human tissues, by immunohistochemistry and in situ hybridization. J. Infect. Dis. 189:1411-1418. http://dx.doi .org/10.1086/383043.
3. Schnittler HJ, Mahner F, Drenckhahn D, Klenk HD, Feldmann H. 1993. Replication of Marburg virus in human endothelial cells. A possible mechanism for the development of viral hemorrhagic disease. J. Clin. Invest. 91:1301-1309.
4. Geisbert TW, Young HA, Jahrling PB, Davis KJ, Larsen T, Kagan E, Hensley LE. 2003. Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am. J. Pathol. 163:2371-2382. http://dx.doi .org/10.1016/S0002-9440(10)63592-4.
5. Green S, Rothman A. 2006. Immunopathological mechanisms in dengue and dengue hemorrhagic fever. Curr. Opin. Infect. Dis. 19:429-436. http: //dx.doi.org/10.1097/01.qco.0000244047.31135.fa.
6. Yang Z, Delgado R, Xu L, Todd RF, Nabel EG, Sanchez A, Nabel GJ. 1998. Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins. Science 279:1034-1037. http://dx.doi.org/10.1126 /science.279.5353.1034.
7. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M, Magner M, Isner JM. 1999. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ. Res. 85:221-228. http://dx .doi.org/10.1161/01.RES.85.3.221.
8. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM. 1997. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275:964-967. http: //dx.doi.org/10.1126/science.275.5302.964.
9. Bahlmann FH, De Groot K, Spandau JM, Landry AL, Hertel B, Duckert T, Boehm SM, Menne J, Haller H, Fliser D. 2004. Erythropoietin regulates endothelial progenitor cells. Blood 103:921-926. http://bloodjournal .hematologylibrary.org/content/103/3/921.long.
10. Bahlmann FH, DeGroot K, Duckert T, Niemczyk E, Bahlmann E, Boehm SM, Haller H, Fliser D. 2003. Endothelial progenitor cell proliferation and differentiation is regulated by erythropoietin. Kidney Int. 64: 1648-1652. http://dx.doi.org/10.1046/j.1523-1755.2003.00279.x.
11. Hattori K, Dias S, Heissig B, Hackett NR, Lyden D, Tateno M, Hicklin DJ, Zhu Z, Witte L, Crystal RG, Moore MA, Rafii S. 2001. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J. Exp. Med. 193:1005-1014. http://dx.doi.org/10.1084/jem.193.9.1005.
12. Heeschen C, Aicher A, Lehmann R, Fichtlscherer S, Vasa M, Urbich C, Mildner-Rihm C, Martin H, Zeiher AM, Dimmeler S. 2003. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 102:1340-1346. http://dx.doi.org/10.1182/blood -2003-01-0223.
13. Kim KL, Shin IS, Kim JM, Choi JH, Byun J, Jeon ES, Suh W, Kim DK. 2006. Interaction between Tie receptors modulates angiogenic activity of angiopoietin2 in endothelial progenitor cells. Cardiovasc. Res. 72:394-402. http://dx.doi.org/10.1016/j.cardiores.2006.08.002.
14. Moore MA, Hattori K, Heissig B, Shieh JH, Dias S, Crystal RG, Rafii S. 2001. Mobilization of endothelial and hematopoietic stem and progenitor cells by adenovector-mediated elevation of serum levels of SDF-1, VEGF, and angiopoietin-1. Ann. N. Y. Acad. Sci. 938:36-45; discussion 45-47. http://dx.doi.org/10.1111/j.1749-6632.2001.tb03572.x.
15. Pitchford SC, Furze RC, Jones CP, Wengner AM, Rankin SM. 2009. Differential mobilization of subsets of progenitor cells from the bone marrow. Cell Stem Cell 4:62-72. http://dx.doi.org/10.1016/j.stem.2008.10.017.
16. Shao H, Tan Y, Eton D, Yang Z, Uberti MG, Li S, Schulick A, Yu H. 2008. Statin and stromal cell-derived factor-1 additively promote angiogenesis by enhancement of progenitor cells incorporation into new vessels. Stem Cells 26:1376-1384. http://dx.doi.org/10.1634/stemcells.2007 -0785.
17. Iwakura A, Luedemann C, Shastry S, Hanley A, Kearney M, Aikawa R, Isner JM, Asahara T, Losordo DW. 2003. Estrogen-mediated, endothelial nitric oxide synthase-dependent mobilization of bone marrowderived endothelial progenitor cells contributes to reendothelialization after arterial injury. Circulation 108:3115-3121. http://dx.doi.org/10 .1161/01.CIR.0000106906.56972.83.
18. Laufs U, Werner N, Link A, Endres M, Wassmann S, Jurgens K, Miche E, Bohm M, Nickenig G. 2004. Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis. Circulation 109:220-226. http://dx.doi.org/10.1161/01.CIR .0000109141.48980.37.
19. Strehlow K, Werner N, Berweiler J, Link A, Dirnagl U, Priller J, Laufs K, Ghaeni L, Milosevic M, Bohm M, Nickenig G. 2003. Estrogen increases bone marrow-derived endothelial progenitor cell production and diminishes neointima formation. Circulation 107:3059-3065. http://dx .doi.org/10.1161/01.CIR.0000077911.81151.30.
20. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, Zeiher AM, Dimmeler S. 2001. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ. Res. 89:E1-E7. http://dx.doi.org/10.1161 /hh1301.093953.
21. Xia WH, Li J, Su C, Yang Z, Chen L, Wu F, Zhang YY, Yu BB, Qiu YX, Wang SM, Tao J. 2012. Physical exercise attenuates age-associated reduction in endothelium-reparative capacity of endothelial progenitor cells by increasing CXCR4/JAK-2 signaling in healthy men. Aging Cell 11:111-119. http://dx.doi.org/10.1111/j.1474-9726.2011.00758.x.
22. Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, Tiemann M, Rutten H, Fichtlscherer S, Martin H, Zeiher AM. 2001. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J. Clin. Invest. 108:391-397. http://dx.doi.org /10.1172/JCI200113152.
23. Llevadot J, Murasawa S, Kureishi Y, Uchida S, Masuda H, Kawamoto A, Walsh K, Isner JM, Asahara T. 2001. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J. Clin. Invest. 108:399-405. http://dx.doi.org/10.1172/JCI200113131.
24. Vasa M, Fichtlscherer S, Adler K, Aicher A, Martin H, Zeiher AM, Dimmeler S. 2001. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 103:2885-2890. http://dx.doi.org/10.1161/hc2401.092816.
25. Dzau VJ, Gnecchi M, Pachori AS, Morello F, Melo LG. 2005. Therapeutic potential of endothelial progenitor cells in cardiovascular diseases. Hypertension 46:7-18. http://dx.doi.org/10.1161/01.HYP.0000168923 .92885.f7.
26. Loomans CJ, de Koning EJ, Staal FJ, Rookmaaker MB, Verseyden C, de Boer HC, Verhaar MC, Braam B, Rabelink TJ, van Zonneveld AJ. 2004. Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes 53:195-199.
27. Rafii S, Lyden D. 2003. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat. Med. 9:702-712. http://dx.doi.org/10.1038/nm0603-702.
28. Schmidt-Lucke C, Rossig L, Fichtlscherer S, Vasa M, Britten M, Kamper U, Dimmeler S, Zeiher AM. 2005. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation 111:2981-2987. http://dx.doi.org/10.1161/CIRCULATIONAHA.104 .504340.
29. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, Bohm M, Nickenig G. 2005. Circulating endothelial progenitor cells and cardiovas-cular outcomes. N. Engl. J. Med. 353:999-1007. http://dx.doi.org/10.1056 /NEJMoa043814.
30. Aird WC. 2003. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood 101:3765-3777. http://dx.doi.org/10 .1182/blood-2002-06-1887.
31. Patschan SA, Patschan D, Temme J, Korsten P, Wessels JT, Koziolek M, Henze E, Muller GA. 2011. Endothelial progenitor cells (EPC) in sepsis with acute renal dysfunction (ARD). Crit. Care. 15:R94. http://dx.doi.org /10.1186/cc10100.
32. Rafat N, Hanusch C, Brinkkoetter PT, Schulte J, Brade J, Zijlstra JG, van der Woude FJ, van Ackern K, Yard BA, Beck G. 2007. Increased circulating endothelial progenitor cells in septic patients: correlation with survival. Crit. Care Med. 35:1677-1684. http://dx.doi.org/10.1097/01 .CCM.0000269034.86817.59.
33. Vaheri A, Strandin T, Hepojoki J, Sironen T, Henttonen H, Makela S, Mustonen J. 2013. Uncovering the mysteries of hantavirus infections. Nat. Rev. Microbiol. 11:539-550. http://dx.doi.org/10.1038/nrmicro306.
34. Vapalahti O, Mustonen J, Lundkvist A, Henttonen H, Plyusnin A, Vaheri A. 2003. Hantavirus infections in Europe. Lancet Infect. Dis. 3:653-661. http://dx.doi.org/10.1016/S1473-3099(03)00774-6.
35. Geimonen E, Neff S, Raymond T, Kocer SS, Gavrilovskaya IN, Mackow ER. 2002. Pathogenic and nonpathogenic hantaviruses differentially regulate endothelial cell responses. Proc. Natl. Acad. Sci. U. S. A. 99:13837-13842. http://dx.doi.org/10.1073/pnas.192298899.
36. Korva M, Saksida A, Kejzar N, Schmaljohn C, Avsic-Zupanc T. 2013. Viral load and immune response dynamics in patients with haemorrhagic fever with renal syndrome. Clin. Microbiol. Infect. 19:E358-E366. http: //dx.doi.org/10.1111/1469-0691.12218.
37. Krautkrämer E, Grouls S, Stein N, Reiser J, Zeier M. 2011. Pathogenic Old World hantaviruses infect renal glomerular and tubular cells and induce disassembling of cell-to-cell contacts. J. Virol. 85:9811-9823. http: //dx.doi.org/10.1128/JVI.00568-11.
38. Lindgren T, Ahlm C, Mohamed N, Evander M, Ljunggren HG, Bjorkstrom NK. 2011. Longitudinal analysis of the human T cell response during acute hantavirus infection. J. Virol. 85:10252-10260. http://dx.doi .org/10.1128/JVI.05548-11.
39. Markotic-A, Hensley L, Daddario K, Spik K, Anderson K, Schmaljohn C. 2007. Pathogenic hantaviruses elicit different immunoreactions in THP-1 cells and primary monocytes and induce differentiation of human monocytes to dendritic-like cells. Coll. Antropol. 31:1159-1167.
40. Pensiero MN, Sharefkin JB, Dieffenbach CW, Hay J. 1992. Hantaan virus infection of human endothelial cells. J. Virol. 66:5929-5936.
41. Pettersson L, Thunberg T, Rocklov J, Klingstrom J, Evander M, Ahlm C. 29 April 2013. Viral load and humoral immune response in association with disease severity in Puumala hantavirus-infected patientsimplications for treatment. Clin. Microbiol. Infect. http://dx.doi.org/10 .1111/1469-0691.12259.
42. Sch-nrich G, Rang A, Lutteke N, Raftery MJ, Charbonnel N, Ulrich RG. 2008. Hantavirus-induced immunity in rodent reservoirs and humans. Immunol. Rev. 225:163-189. http://dx.doi.org/10.1111/j.1600 -065X.2008.00694.x.
43. Robert-Koch-Institut. 2007. Falldefinitionen des Robert Koch-Instituts zur U-bermittlung von Erkrankungs-oder Todesfällen und Nachweisen von Krankheitserregern. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 49:1236-1284. (In German.)
44. Duda DG, Cohen KS, Scadden DT, Jain RK. 2007. A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood. Nat. Protoc. 2:805-810. http: //dx.doi.org/10.1038/nprot.2007.111.
45. Lipkin GW, Kendall R, Haggett P, Turney JH, Brownjohn AM. 1989. Erythropoietin in acute renal failure. Lancet i:1029.
46. Breen EC. 2007. VEGF in biological control. J. Cell. Biochem. 102:1358-1367. http://dx.doi.org/10.1002/jcb.21579.
47. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. 1983. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219:983-985. http://dx.doi.org/10 .1126/science.6823562.
48. Gavrilovskaya I, Gorbunova E, Koster F, Mackow E. 2012. Elevated VEGF levels in pulmonary edema fluid and PBMCs from patients with acute hantavirus pulmonary syndrome. Adv. Virol. 2012:674360. http: //dx.doi.org/10.1155/2012/674360.
49. Li Y, Wang W, Wang JP, Pan L, Zhang Y, Yu HT, Jiang W, Wang PZ, Bai XF. 2012. Elevated vascular endothelial growth factor levels induce hyperpermeability of endothelial cells in hantavirus infection. J. Int. Med. Res. 40:1812-1821. http://dx.doi.org/10.1177/030006051204000519.
50. Ma Y, Liu B, Yuan B, Wang J, Yu H, Zhang Y, Xu Z, Yi J, Zhang C, Zhou X, Yang A, Zhuang R, Jin B. 2012. Sustained high level of serum VEGF at convalescent stage contributes to the renal recovery after HTNV infection in patients with hemorrhagic fever with renal syndrome. Clin. Dev. Immunol. 2012:812386. http://dx.doi.org/10.1155/2012/812386.
51. Shrivastava-Ranjan P, Rollin PE, Spiropoulou CF. 2010. Andes virus disrupts the endothelial cell barrier by induction of vascular endothelial growth factor and downregulation of VE-cadherin. J. Virol. 84:11227-11234. http://dx.doi.org/10.1128/JVI.01405-10.
52. Dvorak HF, Sioussat TM, Brown LF, Berse B, Nagy JA, Sotrel A, Manseau EJ, Van de Water L, Senger DR. 1991. Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels. J. Exp. Med. 174:1275-1278. http://dx .doi.org/10.1084/jem.174.5.1275.
53. Mazzinghi B, Ronconi E, Lazzeri E, Sagrinati C, Ballerini L, Angelotti ML, Parente E, Mancina R, Netti GS, Becherucci F, Gacci M, Carini M, Gesualdo L, Rotondi M, Maggi E, Lasagni L, Serio M, Romagnani S, Romagnani P. 2008. Essential but differential role for CXCR4 and CXCR7 in the therapeutic homing of human renal progenitor cells. J. Exp. Med. 205:479-490. http://dx.doi.org/10.1084/jem.20071903.
54. Clement J, De Bock R, Beguin Y. 1994. Defective Epo production contributes to anemia persistent after ARF in nephropathia epidemica (NE), p 467-473. In Papadimitriou A (ed), Proceedings of the 3rd International Satellite Symposium on Acute Renal Failure. University Studio Press, Thessaloniki, Greece.
55. Nielsen OJ, Thaysen JH. 1989. Erythropoietin deficiency in acute renal failure. Lancet i:624-625.
56. Duchin JS, Koster FT, Peters CJ, Simpson GL, Tempest B, Zaki SR, Ksiazek TG, Rollin PE, Nichol S, Umland ET, Hantavirus Study Group. 1994. Hantavirus pulmonary syndrome: a clinical description of 17 patients with a newly recognized disease. N. Engl. J. Med. 330:949-955. http: //dx.doi.org/10.1056/NEJM199404073301401.
57. Burnham EL, Taylor WR, Quyyumi AA, Rojas M, Brigham KL, Moss M. 2005. Increased circulating endothelial progenitor cells are associated with survival in acute lung injury. Am. J. Respir. Crit. Care Med. 172:854-860. http://dx.doi.org/10.1164/rccm.200410-1325OC.
58. Mahanty S, Bray M. 2004. Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect. Dis. 4:487-498. http://dx.doi.org/10.1016/S1473 -3099(04)01103-X.
59. Peters CJ, Zaki SR. 2002. Role of the endothelium in viral hemorrhagic fevers. Crit. Care Med. 30:S268-73. http://dx.doi.org/10.1097/00003246 -200205001-00016.
60. Balabanova Y, Gilsdorf A, Buda S, Burger R, Eckmanns T, Gartner B, Gross U, Haas W, Hamouda O, Hubner J, Janisch T, Kist M, Kramer MH, Ledig T, Mielke M, Pulz M, Stark K, Suttorp N, Ulbrich U, Wichmann O, Krause G. 2011. Communicable diseases prioritized for surveillance and epidemiological research: results of a standardized prioritization procedure in Germany, 2011. PLoS One 6:e25691. http://dx.doi .org/10.1371/journal.pone.0025691.
61. Klempa B, Witkowski PT, Popugaeva E, Auste B, Koivogui L, Fichet-Calvet E, Strecker T, Ter Meulen J, Kr-ger DH. 2012. Sangassou virus, the first hantavirus isolate from Africa, displays genetic and functional properties distinct from those of other murinae-associated hantaviruses. J. Virol. 86:3819-3827. http://dx.doi.org/10.1128/JVI.05879-11.
62. Memish ZA, Albarrak A, Almazroa MA, Al-Omar I, Alhakeem R, Assiri A, Fagbo S, MacNeil A, Rollin PE, Abdullah N, Stephens G. 2011. Seroprevalence of Alkhurma and other hemorrhagic fever viruses, Saudi Arabia. Emerg. Infect. Dis. 17:2316-2318. http://dx.doi.org/10.3201 /eid1712.110658.
63. Yu XJ, Liang MF, Zhang SY, Liu Y, Li JD, Sun YL, Zhang L, Zhang QF, Popov VL, Li C, Qu J, Li Q, Zhang YP, Hai R, Wu W, Wang Q, Zhan FX, Wang XJ, Kan B, Wang SW, Wan KL, Jing HQ, Lu JX, Yin WW, Zhou H, Guan XH, Liu JF, Bi ZQ, Liu GH, Ren J, Wang H, Zhao Z, Song JD, He JR, Wan T, Zhang JS, Fu XP, Sun LN, Dong XP, Feng ZJ, Yang WZ, Hong T, Zhang Y, Walker DH, Wang Y, Li DX. 2011. Fever with thrombocytopenia associated with a novel bunyavirus in China. N. Engl. J. Med. 364:1523-1532. http://dx.doi.org/10 .1056/NEJMoa1010095.